Eris Lifesciences Q3 profit rises 19% to around ₹100 Cr, revenue up 10%

Eris Lifesciences reported a steady operating performance in the December quarter, supported by healthy growth in revenue and profitability.

Eris Lifesciences Limited’s net profit rose 19% year-on-year to ₹99.7 crore in Q3, compared with ₹83.7 crore in the corresponding quarter last year. Revenue from operations increased 10% YoY to ₹807 crore, up from ₹732 crore in the same period last year.

EBITDA grew 11% YoY to ₹282.3 crore from ₹254.7 crore a year ago. EBITDA margin improved marginally to 35%

in Q3, compared with 34.8% in the year-ago quarter, reflecting stable cost management and operating leverage.

Read More: Eris Lifesciences to acquire remaining 30% in Swiss Parenterals for ₹423 crore